Table 3.

Final models of clinical parameters associated with whole blood mitochondrial DNA copy number adjusted for platelet to leukocyte count.

Variable	B	SE	βstandardized	t	p
Model 1: Clinical profile (adjusted R2 = 0.038, ANOVA: F = 10.7, n = 497)
(Constant)	0.029	0.007		4.51	<0.001
Age	<0.001	<0.001	−0.142	−3.20	0.001
CGI	−0.003	0.001	−0.128	−2.90	0.004
Model 2: Treatment (adjusted R2 = 0.064, ANOVA: F = 9.61, n = 504)
(Constant)	0.03	0.006		4.91	<0.001
Age	−0.001	<0.001	−0.210	−4.74	<0.001
Clozapine	−0.010	0.004	−0.110	−2.52	0.012
Risperidone	−0.009	0.003	−0.109	−2.48	0.014
Model 3 Group A: Treatment vs psychosis severity (adjusted R2 = 0.047, ANOVA: F = 7.70, n = 136)
(Constant)	0.002	0.004		0.402	0.689
Proportion of life on treatment	<0.001	<0.001	−0.232	−2.78	0.006
Model 3 Group B: Treatment vs psychosis severity (adjusted R2 = 0.042, ANOVA: F = 8.46, n = 340)
(Constant)	0.039	0.009		4.39	<0.001
Age	−0.001	<0.001	−0.159	−2.97	0.003
CGI	−0.004	0.001	−0.129	−2.41	0.017
Model 4 Group A: Metabolic profile (adjusted R2 = 0.039, ANOVA: F = 5.93, n = 123)
Proportion of life on treatment	<0.001	<0.001	−0.215	−2.44	0.016
Model 4 Group B: Metabolic profile (adjusted R2 = 0.055, ANOVA: F = 7.13, n = 319)
(Constant)	0.043	0.009		4.56	<0.001
Age	−0.001	0.001	−0.173	−3.17	0.002
CGI	−0.003	0.002	−0.113	−2.07	0.040
LDL	−0.001	<0.001	−0.119	−2.19	0.029

CGI: Clinical Global Impression-Severity.

Group A: patients receiving clozapine or risperidone.

Group B: patients not receiving clozapine or risperidone.